Oruka Therapeutics, Inc. (ORKA) Stock

Oruka Therapeutics, Inc. (ORKA) is a Healthcare stock trading at $92.37 (as of 2026-09-11), with a market capitalization of $6.12B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oruka Therapeutics, Inc. is a biotechnology company developing monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immune (I&I) indications. Its development pipeline includes ORKA-001 and ORKA-002.

Understand Oruka Therapeutics, Inc.: how it makes money

Oruka Therapeutics is developing monoclonal antibody drugs (ORKA-001 and ORKA-002) for psoriasis and other immune-driven inflammatory diseases, with no product revenue yet. The entire investment case rests on whether those two candidates clear late-stage clinical and regulatory hurdles to become sellable treatments.

Value is entirely tied to clinical and regulatory milestones for ORKA-001 and ORKA-002; there is no commercial operation to cushion a pipeline miss.

Business quality (Unprofitable): Pre-revenue biotech; operating margin of -563% reflects heavy R&D spending against zero product sales.

Bull case

  • Two candidates in high-need space: ORKA-001 and ORKA-002 both target psoriasis and immune/inflammatory conditions, giving the company two independent paths to a commercial product. A positive pivotal data readout on either candidate would create immediate licensing or launch value.

Bear case

  • No revenue, deep operating losses: The company generated no product revenue in the period and carries an operating margin of -563%, meaning every dollar of R&D spend deepens the cash burn with no commercial offset to offset it.
  • Binary risk with no diversifier: With only two pipeline assets and zero commercial operations, a single Phase 3 failure or regulatory rejection would eliminate substantially all of the company's enterprise value.
Valuation — source: SEC EDGAR (first-party)
Price$92.37
Market Cap$6.12B
Price / Book5.49
Price / Sales275.68
FCF Yield-1.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$16.63M
Net Margin-634.0%
Return on Equity-11.9%
Current Ratio38.51
Revenue Growth (YoY)130.7%
FCF Growth (YoY)145.0%
Financial Health — source: SEC EDGAR
Altman Z-Score164.02 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)19.4
Industry P/E (Pharmaceutical Products)15.1
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($862.02M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOLawrence Otto Klein
Employees28
CountryUS
IPO Date1997-08-08

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Olema Pharmaceuticals, Inc. (OLMA)
  • Zenas BioPharma, Inc. (ZBIO)
  • Vera Therapeutics, Inc. (VERA)
  • Veru Inc. (VERU)
  • Evommune, Inc. (EVMN)
  • Crescent Biopharma, Inc. (CBIO)
  • Neuphoria Therapeutics Inc. (NEUP)
  • Bicara Therapeutics Inc. (BCAX)
ORKA earnings history · ORKA institutional & insider holders · ORKA KPIs & operating metrics · ORKA financials · ORKA filings, presentations & press releases · ORKA investor presentations & press releases · ORKA SEC filings · ORKA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-11.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.